- Date: March 30, 2017
25 April, second intermediate deadline for proposals to carry out high-quality scientific projects under the Horizon 2020 programme. The final deadline for submission is 5 September, 5:00 p.m. (local time in Brussels). For the first intermediate deadline of this call (19 January 2017), a total of 124 proposals were submitted.
The European Union concentrates much of its research and innovation activities under the framework programme called Horizon 2020, with a budget of almost €80 billion in funding available for 2014-2020. Its main function is to support frontier research, interdisciplinary proposals, and pioneering ideas in new and emerging fields that introduce unconventional and innovative approaches. Its mission is to encourage the highest-quality research in Europe through competitive funding.
Horizon 2020 integrates, for the very first time, all phases starting from knowledge creation to the activities closest to the market: basic research, development of technologies, demonstration projects, pilot lines for manufacturing, social innovation, technology transfer, proof of concept, standardisation, support for pre-commercial procurement, venture capital, and guarantee schemes.
ERC Proof of Concept Grants for ERC grant holders who want to check the market and/or innovation potential of research results from ERC-projects -up to 150,000 euro for a period of 12 months.
The programme’s website:
November 17, 2017
On 10 November, participants pitched their valorisation plans to the CaixaImpulse Valorisation Panel, who will confirm the grants offered to each project. The upcoming months will be devoted to execute the actions included in their respective plans.
November 14, 2017
World Diabetes Day is the largest campaign of its kind to raise awareness of the metabolic disease. CaixaImpulse's APODRUG project aims to develop a new treatment for diabetic patients with an associated fatty liver disease.
November 10, 2017
GlyCardial Diagnostics, which was founded last September, has raised an investment of €2.4 million from Caixa Capital Risc, with participation from the Healthequity SCR fund.